These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 279397)

  • 1. Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
    Legha SS; Gutterman JU; Hall SW; Benjamin RS; Burgess MA; Valdivieso M; Bodey GP
    Cancer Res; 1978 Nov; 38(11 Pt 1):3712-6. PubMed ID: 279397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
    Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
    Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
    Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
    Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
    Woodcock TM; Schneider RJ; Young CW
    Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
    Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
    Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942).
    Von Hoff DD; Myers JW; Kuhn J; Sandbach JF; Pocelinko R; Clark G; Coltman CA
    Cancer Res; 1981 Aug; 41(8):3118-21. PubMed ID: 6265075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer.
    Rivera G; Evans WE; Dahl GV; Yee GC; Pratt CB
    Cancer Res; 1980 Nov; 40(11):4250-3. PubMed ID: 6258775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
    Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
    Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
    Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
    Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
    Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
    Ahmann FR; Meyskens FL; Moon TE; Durie BG; Salmon SE
    Cancer Res; 1982 Nov; 42(11):4495-8. PubMed ID: 6897012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical evaluation of intravenous 4'-(9-acridinylamino)methanesulfon-m-anisidide in colorectal cancer.
    Valdivieso M; Stroehlein JR; Bedikian AY; Karlin DA; Legha SS; Bennetts RW; Bodey GP
    Am J Clin Oncol; 1983 Feb; 6(1):39-44. PubMed ID: 6687657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer.
    Legha SS; Blumenschein GR; Buzdar AU; Hortobagyi GN; Bodey GP
    Cancer Treat Rep; 1979; 63(11-12):1961-4. PubMed ID: 526929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT; Hancock CH; Mondora A; Hoffman NW
    Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
    Alberts DS; Mackel C; Pocelinko R; Salmon SE
    Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
    Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
    Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
    Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
    Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
    [No Abstract]   [Full Text] [Related]  

  • 19. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
    Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
    Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
    Currie VE; Howard J; Wittes R
    Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.